Cansino Biologics (China) Top Management
688185 Stock | 61.23 0.13 0.21% |
Cansino Biologics employs about 1.5 K people. The company is managed by 10 executives with a total tenure of roughly 3486 years, averaging almost 348.0 years of service per executive, having 149.4 employees per reported executive. Analysis of Cansino Biologics' management performance can provide insight into the company performance.
Xuefeng Yu Chairman Chairman, CoFounder |
Cansino |
Cansino Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0792) % which means that it has lost $0.0792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1362) %, meaning that it generated substantial loss on money invested by shareholders. Cansino Biologics' management efficiency ratios could be used to measure how well Cansino Biologics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Cansino Biologics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 481.5 M, whereas Total Assets are forecasted to decline to about 6.7 B.As of December 24, 2024, Common Stock Shares Outstanding is expected to decline to about 259.1 M. The current year's Net Loss is expected to grow to about (993.6 M)
Cansino Biologics Workforce Comparison
Cansino Biologics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 45,276. Cansino Biologics holds roughly 1,494 in number of employees claiming about 3% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.96) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12. Cansino Biologics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cansino Biologics Price Series Summation is a cross summation of Cansino Biologics price series and its benchmark/peer.
Cansino Biologics Notable Stakeholders
A Cansino Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cansino Biologics often face trade-offs trying to please all of them. Cansino Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cansino Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Tao Zhu | Deputy CoFounder | Profile | |
Dongxu MBA | Executive CoFounder | Profile | |
Xuefeng Yu | Chairman, CoFounder | Profile | |
Chunlin Xin | Director Department | Profile | |
ShouBai Chao | COO Director | Profile | |
Yonghui Wu | Vice Marketing | Profile | |
Jin Cui | Board Secretary | Profile | |
Xi Luo | Chief Officer | Profile | |
FCS FCIS | Joint Secretary | Profile | |
Jing Wang | Deputy Officer | Profile |
About Cansino Biologics Management Performance
The success or failure of an entity such as Cansino Biologics often depends on how effective the management is. Cansino Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cansino management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cansino management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cansino Biologics is entity of China. It is traded as Stock on SHG exchange.
Please note, the presentation of Cansino Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cansino Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cansino Biologics' management manipulating its earnings.
Cansino Biologics Workforce Analysis
Traditionally, organizations such as Cansino Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cansino Biologics within its industry.Cansino Biologics Manpower Efficiency
Return on Cansino Biologics Manpower
Revenue Per Employee | 231K | |
Revenue Per Executive | 34.5M | |
Net Loss Per Employee | 968.7K | |
Net Loss Per Executive | 144.7M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 258.9M |
Complementary Tools for Cansino Stock analysis
When running Cansino Biologics' price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |